UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
APRIL 24, 2003
KOSAN BIOSCIENCES INCORPORATED
(Exact name of registrant specified in its charter)
Delaware | 000-31633 | 94-3217016 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employee Identification No.) |
3832 Bay Center Place Hayward, Ca | 94545 | |
(Address of principal executive offices) | (Zip Code) |
Registrant’s Telephone, Including Area Code: (510) 732-8400
Item 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) EXHIBITS
Exhibit | Description | |
99.1 | Press Release dated April 24, 2003, relating to the Company’s financial results for the quarter ended March 31, 2003. |
Item 9. REGULATION FD DISCLOSURE.
In accordance with SEC Release No. 33-8216, the information in this Current Report on Form 8-K is being furnished to, but not filed with, the Securities and Exchange Commission solely under Item 12 of Form 8-K, “Results of Operations and Financial Condition.”
Item 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
On April 24, 2003, Kosan Biosciences Incorporated (the “Company”) announced via a press release the results of its operations for the quarter ended March 31, 2003. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
KOSAN BIOSCIENCES INCORPORATED (Registrant) | ||
By: | /s/ DANIEL V. SANTI, M.D., PH.D | |
Daniel V. Santi, M.D., Ph.D Chairman and Chief Executive Officer |
Dated: April 25, 2003
EXHIBIT INDEX
Exhibit | Description | |
99.1 | Press Release dated April 24, 2003, relating to the Company’s financial results for the quarter ended March 31, 2003. |